Measuring symptom experience of side-effects of immunosuppressive drugs: The modified transplant symptom occurrence and distress scale

被引:71
作者
Dobbels, Fabienne [1 ]
Moons, Philip [1 ]
Abraham, Ivo [2 ,3 ,4 ]
Larsen, Christian P. [5 ]
Dupont, Lieven [6 ]
De Geest, Sabina [1 ,7 ]
机构
[1] Katholieke Univ Leuven, Ctr Hlth Services & Nursing Res, B-3000 Louvain, Belgium
[2] Univ Penn, Ctr Hlth Outcomes & Policy Res, Philadelphia, PA USA
[3] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[4] Matrix 45, Earlysville, VA USA
[5] Emory Univ Hosp, Ctr Transplantat & Transplantat Immunol, Atlanta, GA 30322 USA
[6] Katholieke Univ Leuven Hosp, Lung Transplantat Program, Louvain, Belgium
[7] Univ Basel, Inst Nursing Sci, Basel, Switzerland
关键词
immunosuppression; organ transplantation; patient reported outcomes; side effects; symptom experience;
D O I
10.1111/j.1432-2277.2008.00674.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Measurement of the patients' subjective experience of side-effects of immunosuppressants is a critical post-transplant outcome. This study aimed to update and validate the 45-item Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD) for novel immunosuppressive regimens. We used four steps: (1) literature review to identify immunosuppressant-related symptoms; (2) screening of adverse event forms; (3) international experts' evaluation of the appropriateness of each symptom; and (4) a pilot study in 24 renal transplant patients to test the clarity of instructions and items, and a pilot study in 84 lung transplant patients, to determine content and discriminant validity. Steps 1 and 2 produced a list of 76 symptoms. Clinical experts deemed 59 symptoms as being relevant for assessing symptom experience (step 3). Based on the first pilot testing, items and instructions were adapted to improve clarity. The second pilot testing showed that the updated MTSOSD-59R was easy to complete, that items and instructions were understandable, and that symptom profiles differed between males and females, and between depressed and nondepressed patients (step 4). The MTSOSD-59R is an instrument with established content and discriminant validity for assessing transplant patients' symptom experience of side-effects stemming from currently available immunosuppressive regimens.
引用
收藏
页码:764 / 773
页数:10
相关论文
共 37 条
[1]  
Anderson RB., 1994, DRUG INF J, V28, P89, DOI 10.1177/009286159402800112
[2]   Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile [J].
Artz, MA ;
Boots, JMM ;
Ligtenberg, G ;
Roodnat, JI ;
Christiaans, MHL ;
Vos, PF ;
Moons, P ;
Borm, G ;
Hilbrands, LB .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :937-945
[3]   The emerging role of rituximab in organ transplantation [J].
Becker, Yolanda T. ;
Samaniego-Picota, Milagros ;
Sollinger, Hans W. .
TRANSPLANT INTERNATIONAL, 2006, 19 (08) :621-628
[4]   Quality of life following organ transplantation [J].
Burra, Patrizia ;
De Bona, Manuela .
TRANSPLANT INTERNATIONAL, 2007, 20 (05) :397-409
[5]   The construct and concurrent validity of the EQ-5D in a renal transplant population [J].
Cleemput, I ;
Kesteloot, K ;
Moons, P ;
Vanrenterghem, Y ;
Van Hooff, JP ;
Squifflet, JP ;
De Geest, S .
VALUE IN HEALTH, 2004, 7 (04) :499-509
[6]   Balancing benefits and harms in health care - We need to get better ividence about harms [J].
Cuervo, LG ;
Clarke, M .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7406) :65-66
[7]  
DABBS AD, 2002, PROG TRANSPLANT, V12, P191
[8]   Noncompliance with immunosuppressive therapy: Prevalence and determinants [J].
de Barros, CT ;
Cabrita, J .
TRANSPLANTATION PROCEEDINGS, 2000, 32 (08) :2633-2633
[9]  
De Geest S, 1998, J HEART LUNG TRANSPL, V17, P854
[10]   The patient's appraisal of side-effects: the blind spot in quality-of-life assessments in transplant recipients [J].
De Geest, S ;
Moons, P .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (04) :457-459